Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation reports developments tied to blood volume measurement technology, including commercialization of its FDA-cleared Blood Volume Analysis diagnostics and the BVA-100 Blood Volume Analyzer. Company news commonly covers clinical data, cardiology and critical-care use cases, new customer programs, conference presentations, and product updates for rapid, portable BVA systems.
Daxor also issues updates on financial results, shareholder communications, capital actions, and market expansion for its ezBVA Lab workflow and related diagnostic services. Its coverage centers on precision fluid management, heart failure, ICU care, and adoption of direct blood, plasma, and red-cell volume measurement in clinical settings.
Daxor Corporation (Nasdaq: DXR) has become a corporate member of the Heart Failure Society of America (HFSA) to enhance engagement with heart failure leaders. This collaboration aims to improve patient outcomes as heart failure affects over 6 million Americans, with nearly 1 million deaths annually. CEO Michael Feldschuh highlighted the opportunity to advance their BVA-100 technology for better product adoption. The membership allows access to HFSA leadership and year-round brand promotion, with goals to expand their user base and products in 2023.
Daxor Corporation (Nasdaq: DXR) announced its participation in the 2023 Critical Care Congress by the Society for Critical Care Medicine, scheduled from January 21 to 24 in San Francisco.
CEO Michael Feldschuh emphasized the congress as a significant opportunity to expand business, focusing on the critical care market's demand for volume management solutions. Daxor's BVA-100® (Blood Volume Analyzer) has shown promising results in improving patient outcomes, including a 66% reduction in mortality in surgical ICU settings. The company aims to enhance healthcare through optimal fluid management and has conducted over 60,000 tests at leading hospitals.
Daxor Corporation (Nasdaq: DXR) announces a groundbreaking study published in the Journal of Cardiovascular Translational Research. The research highlights the inaccuracy of pressure measures in assessing blood volume in heart failure patients compared to the BVA-100 blood test. Results showed a significant lack of correlation between PADP and total blood volume (TBV) measurements, emphasizing the 98% accuracy of direct volume measurement. The study reinforces the importance of blood volume analysis in improving patient outcomes and management in heart failure, supported by extensive published research.
Daxor Corporation (Nasdaq: DXR) has successfully closed its underwritten public offering, issuing 210,527 shares at $9.50 per share, generating gross proceeds of approximately $2.1 million. The offering was slightly increased by the underwriter's partial exercise of an over-allotment option, which added 10,523 shares. Proceeds will be utilized for working capital, product development, capital expenditures, and potential acquisitions. The offering was conducted under an effective shelf registration statement filed with the SEC.
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, has priced a public offering of 210,527 shares at $9.50 per share, aiming for gross proceeds of $2.0 million. The offering includes an additional option for underwriters to purchase up to 10,527 extra shares. The net proceeds will be allocated towards working capital, product development, and potential acquisitions. The offering is set to close on November 17, 2022, pending customary conditions.
Daxor Corporation (Nasdaq: DXR) announced an underwritten public offering of its common stock, with the lead underwriter Joseph Gunnar & Co., LLC. Daxor may offer an additional 15% of the shares sold, with proceeds intended for working capital, product development, acquisitions, and to repay outstanding debt. The offering's terms are subject to market conditions, and a preliminary prospectus is available through the SEC's website. The company has successfully conducted over 60,000 blood volume tests, showcasing its leadership in this medical field.
Daxor Corporation (Nasdaq: DXR) announces its BVA-100 diagnostic will be featured in a MedAxiom Academy webinar on November 17, 2022, focusing on best practices for blood volume analysis in heart failure. This collaboration aims to raise awareness among healthcare executives to improve heart failure outcomes, reduce costs, and enhance overall care quality. The BVA technology has demonstrated a significant reduction in heart failure readmissions and mortality rates. Registration for the free webinar is open to all.
Daxor Corporation (Nasdaq: DXR) announced a study published in the Journal of Cardiac Failure that highlights the effectiveness of its BVA-100 blood test for assessing heart failure. The study demonstrated that traditional surrogate markers fail to measure intravascular volume overload accurately, an essential factor in managing heart failure. The BVA-100 has shown a critical role in reducing hospital readmissions and improving patient outcomes for over 6 million Americans suffering from heart failure. CEO Michael Feldschuh emphasized the test's clinical importance in guiding treatment decisions.
Daxor Corporation (Nasdaq: DXR) will attend the American Heart Association Scientific Sessions from November 5-7, 2022, in Chicago, IL. This event gathers over 15,000 experts in cardiovascular research. The company emphasizes the effectiveness of its BVA guided treatment in heart failure, which can significantly lower 30-day readmissions by 56%, mortality by 82%, and hospital stays by 55%. Daxor's BVA-100® is the first FDA-cleared diagnostic blood test for quantifying blood volume, with over 60,000 tests conducted in leading U.S. hospitals.
Daxor Corporation (Nasdaq: DXR) announced a scientific debate titled "Debating Volume-based versus Pressure-based Methods and Devices to Measure Congestion in Heart Failure" at the Heart Failure Society of America Annual Scientific Meeting on October 3, 2022. Experts agreed that Daxor's BVA-100 blood test, the only FDA-cleared diagnostic for quantifying blood volume, is crucial for managing heart failure. The test has been conducted over 60,000 times in U.S. hospitals, demonstrating its clinical value in improving patient outcomes, including reduced mortality and readmissions.